

June 2024 Activities Report and Appendix 4C

Key points:

- **PTX-100 Phase 1b results presented at international T-cell lymphoma conference with positive reception from global lymphoma and industry experts**
- **Last patient in Phase 1b T-cell lymphoma trial achieves a complete response**
- **Ongoing strategic clinical, regulatory and commercial input into design of Phase 2 trial of PTX-100 to optimise trial in areas of unmet medical need**
- **Ongoing progress on cell therapy platforms with third party interest in CellPryme**
- **Cash and term deposit balance of \$14.5 million with spending in line with budget**

MELBOURNE Australia, 31 July 2024: Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, today reported its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the June 2024 quarter.

Financial summary

Prescient ended the quarter with cash reserves of \$14.5 million (\$15.8 million on 31 March 2024) of which \$4.0 million was held in term deposits with maturities greater than three months. Net operating expenditure during the quarter was \$1.4 million, in line with budget. A total of \$1.1 million was invested in R&D and clinical development activities.

The business is operating with a cash runway of 10.7 quarters based on net cash used during the quarter, however, expenditure is expected to increase later this year commensurate with an increase in clinical trial activities. Payments to related parties of the entity and their associates amounted to \$179,000 and were directly related to non-executive director fees, executive director salary and superannuation.

PTX-100 activity summary

Prescient has been deeply immersed in activities pertaining to the Phase 2 trial of PTX-100. In particular, Prescient has been diligently working to review and refine the trial design. The Company has incorporated feedback from key opinion leaders in the field of T-Cell Lymphoma (TCL) as well as regulatory, manufacturing and commercial experts. This guidance aims to optimise the trial's potential for success, focus on the greatest areas of unmet medical need and minimise the time and resources required to conduct the study. This work has resulted in Prescient actively deferring its planned US Food and Drug

Administration (FDA) meeting and the Company is confident the additional planning and advice will be of considerable net benefit.

The Company plans to hold a meeting with the FDA with the revised trial strategy in the coming months, and aims to commence the Phase 2 trial before the end of this calendar year. The Company looks forward to sharing trial design in the near future.

By taking the time to carefully refine the trial design, Prescient is positioning itself for greater success in the long run. This approach to optimise the efficiency of the clinical path for PTX-100 should ultimately lead to more effective therapies and better outcomes for patients sooner, which is the Company's primary goal.

Substantial Chemistry, Manufacturing, and Control (CMC) activities are ongoing to support PTX-100's development plans. CMC requirements for programs preparing for registration studies are considerably more detailed and stringent than for earlier stage clinical studies.

Prescient Phase 1b data well received at TCLF24

In June, Prescient was invited to give a plenary presentation to the 15th Annual T-Cell Lymphoma Forum (TCLF) in California to present the Phase 1b results of PTX-100 in patients with relapsed and refractory T-cell lymphomas (r/r TCLs). The TCLF is a specialist conference dedicated to the latest developments in TCLs that gathers clinicians, scientists, and industry participants focused on T-cell lymphomas. The forum is known for featuring cutting-edge research, novel agents, and innovative treatment approaches.

The PTX-100 study results were presented by the Principal Investigator, Professor H. Miles Prince, AM, who is a globally renowned expert in TCLs.

Feedback from the TCLF was overwhelmingly positive, with particularly positive feedback on PTX-100's safety profile and the durations of response. There were extremely productive discussions on trial design, and interest from leading international clinicians to participate in the Phase 2 study. Several in-depth conversations were also conducted with commercial companies that are active in the field of TCLs.

Patient update

Following the reporting period, Prescient is delighted to report that the last patient enrolled to the Phase 1b study has experienced a complete response (complete eradication of disease). This patient is a 51-year-old woman with CTCL who had failed three prior therapies. This result further bolsters an already encouraging body of data from this study in a patient population characterised by unmet need and poor outcomes.

Cell therapy platforms

CellPryme

Prescient and its collaborators at the Peter MacCallum Cancer Centre (PMCC) are completing studies that further detail the effects of CellPryme on the tumour microenvironment (TME). The TME is the complex ecosystem that surrounds tumours inside the body which significantly influences cancer progression. Moreover, the TME can significantly inhibit the effectiveness of cancer therapies, including cell therapies. If successful, these studies could shed additional light on how CellPryme can play a role in overcoming TME resistance to enhance cell therapies.

Prescient has progressed discussions with several potential partners to evaluate CellPryme-M. Whilst these discussions take time to evaluate, Prescient is pleased to report that several of these are progressing in parallel.

Prescient is also manufacturing additional clinical grade CellPryme-A suitable for clinical studies, as the Company prepares for first-in-human clinical studies to assess CellPryme-A in combination with CAR-T therapies. Whilst the cell therapies malaise persists, Prescient continues to evaluate and pursue third-party opportunities to clinically evaluate CellPryme-A to enhance cell therapies.

OmniCAR

Prescient has been working with collaborators at the PMCC, as well as the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in the troubleshooting of OmniCAR. This has involved multi-disciplinary expertise in cell biology, protein engineering and bioinformatics. OmniCAR variants have been designed and are being tested.

New team members

Non-executive Director

After the reporting period, Prescient announced the appointment of Dr Gavin Shepherd as a Non-executive Director of the Company. Dr Shepherd is an accomplished medical professional with 25 years of experience in medicine and a proven track record in driving success in various specialist consulting businesses. After completing his medical qualification at Flinders University, he completed specialist training as a consultant Occupational and Environmental Physician with a fellowship from the Royal Australasian College of Physicians. He graduated dux of his Graduate Diploma in OH+S at Adelaide University and he completed his GAICD qualification in 2011. He is a serial Australian biotech investor, with a considerable shareholding in Prescient. Dr Shepherd is also a non-executive director of Lateral Pharma Pty Ltd.

Director of Clinical Development and Translational Sciences

Prescient also recently welcomed Dr Mariam Mansour as Director of Clinical Development and Translational Sciences. Dr Mansour joins Prescient from CSL, where she was a Research and Clinical Lead. Prior to that, Dr Mansour was a Senior Research Fellow at the PMCC, where she led preclinical development initiatives for early-stage portfolio assets at Bristol Myers Squibb and Genentech.

Dr Mansour has over 17 years of experience in clinical development, particularly in biologics, gene, and cell therapy products, where she has been involved in developing therapeutic area portfolio strategies; managing clinical pipelines; and implementing biomarker and bioanalytical strategies. Her expertise is perfectly suited to supporting Prescient's programs at this exciting time.

Summary

With the advent of the Phase 2 study of PTX-100, Prescient will reach the beginning of an important value inflection, which builds on many years of hard work. Data from the Phase 1b study continues to impress international lymphoma experts, as the industry looks to address this area of major unmet need.

Additionally, Prescient is well positioned to take advantage of a recovery in the cell therapy sector, with two platform technologies in CellPryme and OmniCAR that can enhance third party cell therapy programs.

- Ends -

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound is currently in a Phase 1b/2 trial in relapsed and refractory AML, where it has resulted in 4 complete remissions so far. PTX-200 previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer.

Cell Therapies

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries

Ally Leiba
Reach Markets
1300 805 795
ir@reachmarkets.com.au

Media enquiries

Andrew Geddes
CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry

development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward- looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: [Supplemental COVID-19 Risk Factors](#)

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Prescient Therapeutics Limited

ABN

56 006 569 106

Quarter ended ("current quarter")

30 June 2024

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(1,088)	(7,354)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(290)	(1,270)
(f) administration and corporate costs	(285)	(1,895)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	312	760
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	2,368
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,351)	(7,391)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(g) entities	-	-
(h) businesses	-	-
(i) property, plant and equipment	-	(1)

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(j) investments in term deposits with maturities longer than 3 months at acquisition	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	12,000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	11,999

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	18
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	18

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	11,848	5,895
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,351)	(7,391)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	11,999
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	18
4.5	Effect of movement in exchange rates on cash held	(5)	(29)
4.6	Cash and cash equivalents at end of period	*10,492	*10,492

** In addition to the cash and cash equivalents balance above as at 30 June 2024, the Company holds an additional \$4 million in term deposits with maturity terms 3 months (31 March 2024: \$4 million), classified in the statement of financial position as short-term investments in accordance with AASB.*

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4,492	2,848
5.2	Call deposits*	6,000	9,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	**10,492	**11,848

**The call deposits included in item 5.2 above, have maturities ranged between 1 month and 3 months at 30 June 2024.*

*** In addition to the cash and cash equivalents balance above as at 30 June 2024, the Company holds an additional \$4 million in term deposits with maturity terms greater than 3 months (31 March 2024: \$4 million), classified in the statement of financial position as short-term investments in accordance with AASB.*

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	179
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Premium financing)	330	330
7.4	Total financing facilities	330	330
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. Financier: Clearmatch Originate Pty Limited Interest rate: 3.09% Maturity date: 25 January 2025 Secured by the underlying insurance policies		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,351)
8.2	Cash and cash equivalents at quarter end (item 4.6)	10,492
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	*10,492
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	*7.8
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
<i>* In addition to the cash and cash equivalents balance noted above at 8.4, the Company holds an additional \$4 million in term deposits, classified in the statement of financial position as short-term investments in accordance with AASB, due to the maturity date being greater than 3 months. As a result, the estimated quarters of funding available will be greater than the figure provided in 8.5 due to holding these additional short-term investments. On a pro-forma basis with the \$4 million included, the Company would have estimated quarters of funding available amounting to 10.7.</i>		

8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: N/A
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
	N/A
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
	N/A
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	N/A
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2024

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.